Results 61 to 70 of about 75,416 (289)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Transcatheter mitral valve replacement (TMVR) for degenerated mitral valve bioprosthesis - A case series

IHJ Cardiovascular Case Reports, 2023
Mitral regurgitation (MR) is the leading cause of heart valve disease worldwide. In aging population, the incidence of mitral regurgitation (MR) has gradually surpassed that of aortic valve stenosis.
Viveka Kumar, Mitendra Singh Yadav, Sangeeta Dhir   +2 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Diffuse Alveolar Hemorrhage due to Acute Mitral Valve Regurgitation

Case Reports in Pulmonology, 2013
Diffuse alveolar hemorrhage (DAH) can be caused by several etiologies including vasculitis, drug exposure, anticoagulants, infections, mitral valve stenosis, and regurgitation.
Creticus P. Marak, Parijat S. Joy, Pragya Gupta, Yana Bukovskaya, Achuta K. Guddati   +4 more
doaj   +1 more source

Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation

, 2004
ObjectivesWe sought to characterize the temporal return of mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation; to identify its predictors, particularly with respect to annuloplasty type; and to determine whether ...
McGee, Edwin C., Cosgrove, Delos M., Rajeswaran, Jeevanantham, Najam, Farzad, Sabik, Joseph F., Blackstone, Eugene H., Lytle, Bruce W., Gillinov, A. Marc, Shiota, Takahiro, Cohen, Gideon, McCarthy, Patrick M.   +10 more
core   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Biomarkers in Mitral Regurgitation

Progress in Cardiovascular Diseases, 2017
Mitral regurgitation (MR) is a common cause of heart failure but may also remain silent without either symptoms or altered cardiac function. In the latter case, management is still controversial and biomarkers could be an important means to solving remaining issues in MR management.
Magnus, Bäck, Rodolfo, Pizarro, Marie-Annick, Clavel   +2 more
openaire   +3 more sources

Impact of Residual Mitral Regurgitation on Survival After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation.

, 2021
OBJECTIVES The aim of this study was to assess the impact of residual mitral regurgitation (resMR) on mortality with respect to left ventricular dilatation (LV-Dil) or right ventricular dysfunction (RV-Dys) in patients with secondary mitral ...
Näbauer, Michael, Butter, Christian, Orban, Mathias, Karam, Nicole, Schofer, Niklas, Stolz, Lukas, Thiele, Holger, Hausleiter, Jörg, Massberg, Steffen, Neuss, Michael, Petrescu, Aniela, Ludwig, Sebastian, Windecker, Stephan, Praz, Fabien, Pfister, Roman, Higuchi, Satoshi, Baldus, Stephan, von Bardeleben, Stephan, Braun, Daniel, Lurz, Philipp, Unterhuber, Matthias, Park, Sang-Don, Kassar, Mohammad, Wild, Mirjam G., Iliadis, Christos, Kalbacher, Daniel   +25 more
core   +1 more source

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source